Piperlongumine Improves Lipopolysaccharide-Induced Amyloidogenesis by Suppressing NF-KappaB Pathway

Neuromolecular Med. 2018 Sep;20(3):312-327. doi: 10.1007/s12017-018-8495-9. Epub 2018 May 25.

Abstract

Amyloidogenesis is known to cause Alzheimer's disease. Our previous studies have found that lipopolysaccharide (LPS) causes neuroinflammation and amyloidogenesis through activation of nuclear factor kappaB (NF-κB). Piperlongumine (PL) is an alkaloid amide found naturally in long pepper (Piper longum) isolates; it was reported to have inhibitory effects on NF-κB activity. We therefore investigated whether PL exhibits anti-inflammatory and anti-amyloidogenic effects by inhibiting NF-κB. A murine model of LPS-induced memory impairment was made via the intraperitoneal (i.p.) injection of LPS (0.25 mg/kg/day, i.p.). We then injected PL (1.5 or 3.0 mg/kg/day, i.p.) for 7 days in three groups of mice to observe effects on memory. We also conducted an in vitro study with astrocytes and microglial BV-2 cells, which were treated with LPS (1 µg/mL) or PL (0.5 or 1.0 or 2.5 µM). Results from our behavioral tests showed that PL inhibited LPS-induced memory. PL also prevented LPS-induced beta-amyloid (Aβ) accumulation and inhibited the activities of β- and γ-secretases. The expression of inflammatory proteins also was decreased in PL-treated mice, cultured BV-2, and primary astrocyte cells. These effects were associated with the inhibition of NF-κB activity. A docking model analysis and pull-down assay showed that PL binds to p50. Taken together, our findings suggest that PL diminishes LPS-induced amyloidogenesis and neuroinflammation by inhibiting NF-κB signaling; PL therefore demonstrates potential for the treatment of Alzheimer's disease.

Keywords: Alzheimer’s disease; Amyloidogenesis; Beta-amyloid; Neuroinflammation; Nuclear factor kappaB; Piperlongumine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / biosynthesis
  • Animals
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Cell Death / drug effects
  • Cells, Cultured
  • Cytokines / antagonists & inhibitors
  • Dioxolanes / administration & dosage
  • Dioxolanes / pharmacology*
  • Dioxolanes / therapeutic use
  • Disease Models, Animal
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Lipopolysaccharides / pharmacology
  • Male
  • Memory / drug effects
  • Mice
  • Microglia / drug effects
  • Microglia / metabolism
  • NF-kappa B p50 Subunit / antagonists & inhibitors*
  • NF-kappa B p50 Subunit / metabolism
  • Piper / chemistry

Substances

  • Amyloid beta-Peptides
  • Cytokines
  • Dioxolanes
  • Lipopolysaccharides
  • NF-kappa B p50 Subunit
  • piperlongumine